Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam Therapeutics (NASDAQ:BEAM). He rated the stock Buy with a target price of $80, implying a substantial 201% upside. Dragon Images/Shutterstock.com Trucchio’s rating and huge upside forecasts are based on highly encouraging data from Beam Therapeutics’ (NASDAQ:BEAM) BEACON trial. The trial results indicate that rist ...